Csl Ltd has released a press release.
CSL Capital Markets Day
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from CSL
- Seqirus and Vaccine Industrial Company sign landmark Memorandum of Understanding with Ministry of Health to localize manufacturing of cell-based seasonal and pandemic influenza vaccines
- CSL 2025 AGM Chair and CEO Speech and Presentation
- CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
- Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
- CSL: Seqirus Presents Latest Research Across Leading Seasonal Influenza Vaccine Portfolio at ESWI 2025
Later from CSL
- CSL to invest approximately $1.5b in U.S. to manufacture plasma-derived therapies
- Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
- Paul McKenzie retires, Gordon Naylor appointed interim CEO
- CSL Half Year Results Announcement
- CSL Statutory Accounts for the Half Year Ended 31 December
Follow CSL into a list and get an email when it puts out news.
Follow CSL